Voluntary announcement - completion of capital Increase of a subsidiary
Filed with HKEX · Stock code 1541 · · 2 pages · English
Summary by 6ix AI
This filing is a voluntary announcement regarding the completion of a capital increase of a subsidiary by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. The announcement informs shareholders and potential investors about the latest business development of the Group, confirming that the capital increase and registration procedures have been completed. The Target Company, ImmuneCare Biopharmaceutical (Shanghai) Co., Ltd., is now a non-wholly owned subsidiary engaged in the development of innovative drugs for metabolic and rare diseases.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
ImmuneOnco Biopharmaceuticals (Shanghai) Inc on 6ix
Earlier from ImmuneOnco Biopharmaceuticals (Shanghai)
- 2026 Interim Report
- ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China
- Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago
- Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025
Later from ImmuneOnco Biopharmaceuticals (Shanghai)
- Next Day Disclosure Return
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September, 2026
- Proposed change of auditor
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 October, 2026
Follow ImmuneOnco Biopharmaceuticals (Shanghai) into a list and get an email when it puts out news.
Follow ImmuneOnco Biopharmaceuticals (Shanghai)